Loading...

Rising Regulatory Hurdles Will Undercut Pharmaceutical Profits Despite Pipeline Hope

Published
08 Apr 25
Updated
30 Apr 25
n/a
n/a
AnalystLowTarget's Fair Value
n/a
Loading
1Y
0.8%
7D
2.7%

Author's Valuation

US$244.4% overvalued intrinsic discount

AnalystLowTarget Fair Value

Shared on 30 Apr 25

Fair value Increased 0.63%

AnalystLowTarget has increased revenue growth from -3.2% to -2.9%.

Shared on 23 Apr 25

Fair value Decreased 6.73%

AnalystLowTarget has increased revenue growth from -2.9% to -3.2%.

Shared on 16 Apr 25

Fair value Decreased 1.77%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on 10 Apr 25

Fair value Increased 13%

AnalystLowTarget has increased revenue growth from -2.0% to -2.9%.